These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9636614)

  • 1. Comparison of neoral and sandimmun cyclosporines for de novo lung transplantation in cystic fibrosis patients.
    Mikhail G; Eadon H; Leaver N; Khaghani A; Yacoub M; Banner N
    Transplant Proc; 1998 Jun; 30(4):1510-1. PubMed ID: 9636614
    [No Abstract]   [Full Text] [Related]  

  • 2. An investigation of the pharmacokinetics, toxicity, and clinical efficacy of Neoral cyclosporin in cystic fibrosis patients.
    Mikhail G; Eadon H; Leaver N; Rogers P; Stephens D; Banner N; Khaghani A; Yacoub M
    Transplant Proc; 1997; 29(1-2):599-601. PubMed ID: 9123148
    [No Abstract]   [Full Text] [Related]  

  • 3. Sandimmun neoral improves the bioavailability of cyclosporin A and decreases inter-individual variations in patients affected with cystic fibrosis.
    Girault D; Haloun A; Viard L; Bellon G; Gottrand F; Guillemain R; Lenoir G; Ladurie FL; Plouvier E; Storni V
    Transplant Proc; 1995 Aug; 27(4):2488-90. PubMed ID: 7652899
    [No Abstract]   [Full Text] [Related]  

  • 4. Conversion from standard cyclosporine to Neoral in lung transplant recipients.
    Kesten S; Scavuzzo M; Laurin L; Tan A; Chaparro C
    Transplant Proc; 1998 Aug; 30(5):1895-7. PubMed ID: 9723324
    [No Abstract]   [Full Text] [Related]  

  • 5. The Swedish nationwide experience of converting transplant patients treated with Sandimmun to the new galenic formulation Sandimmun-neoral. The Swedish Sandimmun-Neoral Conversion Group.
    Wilczek HE; Berglin E; Blohmé I; Bäckman L; Fehrman I; Källen R; Nyberg G; Säwe J; Wahlberg J
    Transplant Proc; 1997; 29(1-2):280-3. PubMed ID: 9122995
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical impact of Neoral in thoracic organ transplantation.
    Aziz T; el-Gamel A; Keevil B; Krysiak P; Campbell C; Rahman A; Deiraniya A; Yonan N
    Transplant Proc; 1998 Aug; 30(5):1900-3. PubMed ID: 9723326
    [No Abstract]   [Full Text] [Related]  

  • 7. Population pharmacokinetics of cyclosporine: influence of covariables and assessment of cyclosporine absorption in kidney, lung, heart and heart + lung transplanted patients.
    Kyhl LE; Rasmussen SN; Aarons L; Jensen SB
    Transplant Proc; 1998 Aug; 30(5):1680. PubMed ID: 9723241
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis.
    Walker S; Habib S; Rose M; Yacoub M; Banner N
    Transplant Proc; 1998 Jun; 30(4):1519-20. PubMed ID: 9636618
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetic profile and variability of cyclosporine versus neoral in patients with cystic fibrosis after lung transplantation.
    Kesten S; Scavuzzo M; Chaparro C; Szalai JP
    Pharmacotherapy; 1998; 18(4):847-50. PubMed ID: 9692659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of conversion from once daily Sandimmun to twice daily Neoral cyclosporine in renal allograft recipients.
    Vathsala A; Lee WT; Lu YM; Woo KT
    Transplant Proc; 1998 Aug; 30(5):1746-8. PubMed ID: 9723264
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study.
    Iversen M; Nilsson F; Sipponen J; Eiskjaer H; Mared L; Bergan S; Nyström U; Fagertun HE; Solbu D; Simonsen S
    J Heart Lung Transplant; 2009 Sep; 28(9):919-26. PubMed ID: 19716045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sandimmun-to-Neoral conversion in stable pediatric kidney transplant recipients.
    Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R
    Transplant Proc; 1998 Aug; 30(5):1995-6. PubMed ID: 9723366
    [No Abstract]   [Full Text] [Related]  

  • 13. Neoral conversion in stable thoracic transplant patients leads to dose reduction.
    Zaldonis DB; Keenan RJ; Pham SM; Kormos RL; Griffith BP
    Transplant Proc; 1998 Aug; 30(5):1898-9. PubMed ID: 9723325
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term safety and efficacy of Neoral in heart transplantation.
    Yonan NA; Aziz T; el-Gamel A; Campbell CS; Rahman AN; Deiraniya AK
    Transplant Proc; 1998 Aug; 30(5):1906-9. PubMed ID: 9723328
    [No Abstract]   [Full Text] [Related]  

  • 15. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
    Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
    Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
    [No Abstract]   [Full Text] [Related]  

  • 16. Abbreviated kinetic profiles to estimate exposure to CyA in renal allograft recipients treated with Sandimmun-Neoral.
    Serafinowicz A; Gaciong Z; Majchrzak J; Baczkowska T; Nowacka E; Gradowska L; Rowiński W; Lao M
    Transplant Proc; 1997; 29(1-2):277-9. PubMed ID: 9122994
    [No Abstract]   [Full Text] [Related]  

  • 17. Cyclosporine pharmacokinetics in stable renal transplant patients: effect of formulation Sandimmun versus Consupren versus Neoral.
    Masri MA; Barbari A; Stephan A; Kamel G; Frem G; Younan F; Rizk S; Moubarak R; Karam A
    Transplant Proc; 1996 Jun; 28(3):1318-20. PubMed ID: 8658676
    [No Abstract]   [Full Text] [Related]  

  • 18. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral.
    Vathsala A; Lee WT; Jacob E; Woo KT
    Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678
    [No Abstract]   [Full Text] [Related]  

  • 19. Case study: de novo application of Neoral in renal transplantation.
    Kahan BD
    Transplant Proc; 1996 Aug; 28(4):2189-91; discussion 2192, 2195. PubMed ID: 8769196
    [No Abstract]   [Full Text] [Related]  

  • 20. Improved absorption and bioavailability of cyclosporine A from a microemulsion formulation in lung transplant recipients affected with cystic fibrosis.
    Reynaud-Gaubert M; Viard L; Girault D; Bertault-Perez P; Guignard M; Metras D; Fuentes P
    Transplant Proc; 1997 Aug; 29(5):2450-3. PubMed ID: 9270807
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.